EU vs US Clinical Data Conundrum: Careful Assessment Needed With Current State Of Flux
This article was originally published in Clinica
Executive Summary
Where are companies best advised to obtain their clinical data, the EU or the US, and why? These are questions Amanda Maxwell put to Patrick Biggins and Michelle McDonough of US consultancy Musculoskeletal Clinical Regulatory Advisers
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.